Wall Street Zen Upgrades Acrivon Therapeutics (NASDAQ:ACRV) to “Hold”

Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently commented on ACRV. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Finally, Piper Sandler raised their target price on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Acrivon Therapeutics Stock Performance

Shares of NASDAQ:ACRV opened at $1.53 on Friday. Acrivon Therapeutics has a 1-year low of $1.05 and a 1-year high of $5.96. The company’s fifty day moving average is $2.01 and its two-hundred day moving average is $1.90. The stock has a market capitalization of $48.29 million, a price-to-earnings ratio of -0.72 and a beta of 1.74.

Insider Activity at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen purchased 49,000 shares of Acrivon Therapeutics stock in a transaction dated Wednesday, January 14th. The stock was bought at an average cost of $1.68 per share, with a total value of $82,320.00. Following the purchase, the chief executive officer owned 2,095,771 shares in the company, valued at approximately $3,520,895.28. The trade was a 2.39% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired 67,832 shares of company stock worth $114,534 over the last quarter. 8.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Acrivon Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrature Capital Ltd acquired a new stake in shares of Acrivon Therapeutics during the 2nd quarter valued at $26,000. Focus Partners Wealth acquired a new stake in shares of Acrivon Therapeutics during the third quarter worth $36,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Acrivon Therapeutics during the fourth quarter worth $40,000. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Acrivon Therapeutics during the fourth quarter valued at $44,000. Finally, Invesco Ltd. acquired a new position in shares of Acrivon Therapeutics in the 1st quarter valued at $72,000. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.